Title:
SUBSTITUTED HETEROARYL COMPOUND, COMPOSITION OF SAME, AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/182188
Kind Code:
A1
Abstract:
Related to the field of pharmaceutics, specifically related to a substituted heteroaryl compound as represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite or pharmaceutically acceptable sale of same, a pharmaceutical composition comprising the compound, and uses of the compound and of the pharmaceutical composition thereof in preparing a medicament for treating proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals. The compound provided exhibits great inhibiting activity and optimized kinase selectivity with respect to a target kinase. In addition, the compound provided also has excellent transmembrane properties, exhibits excellent pharmacokinetic properties in an animal body; therefore, the compound provided has great development prospects.
Inventors:
XI NING (US)
Application Number:
PCT/CN2020/078990
Publication Date:
September 17, 2020
Filing Date:
March 12, 2020
Export Citation:
Assignee:
XI FENG (CN)
International Classes:
C07D487/04; A61K31/519; A61P35/00; A61P37/02
Domestic Patent References:
| WO2015068767A1 | 2015-05-14 |
Foreign References:
| CN108250200A | 2018-07-06 |
Other References:
RHO J K; CHOI Y J; KIM S Y; KIM T W; CHOI E K; S-J YOON; PARK B M; PARK E; BAE J H; C-M CHOI; LEE J C: "MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation", CANCER RESEARCH, vol. 74, no. 1, 28 October 2013 (2013-10-28), pages 253 - 262, XP055273129, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-13-1103
Download PDF: